Cullinan Oncology Inc SEC Filings

Cullinan Therapeutics disclosed that Lynx1 Capital Management LP and Weston Nichols collectively report beneficial ownership of 4,400,842 shares, representing 7.5% of the outstanding common stock based on 59,014,667 shares outstanding as of April 30, 2025. The holdings are reported as shared voting and dispositive power, with no sole voting or dispositive power indicated.

This Schedule 13G filing identifies the investment manager (Lynx1) and Mr. Nichols as reporting persons and states the shares are held by the Lynx1 Master Fund. The filing includes a certification that the position was not acquired to change or influence control of the company.

Cullinan Therapeutics director Doyle Mittie received a stock option award to purchase 79,456 shares of the company’s common stock. The grant has an exercise price of $7.03 per share and was transacted on 08/07/2025. The option vests in three equal installments: one-third on each of the first, second and third anniversaries of the grant date, conditioned on the Reporting Persons continued service as a director.

The option is held directly, the reported number of derivative securities beneficially owned after the transaction is 79,456, and the option has an indicated expiration date of 08/07/2035.

Cullinan Therapeutics director Andrew R. Allen was granted a stock option on 08/07/2025 to purchase 79,456 shares of the company's common stock at an exercise price of $7.03 per share. The option vests in three equal installments—one-third on each of the first, second and third anniversaries of the grant date—subject to continued service as a director, and the instrument expires on 08/07/2035.

The reported transaction shows the reporting person beneficially owning 79,456 shares following the award. The filing documents a routine director equity award that creates the right to acquire shares over time under standard vesting conditions.

Citadel Advisors LLC and related Citadel entities, along with founder Kenneth Griffin, disclosed a new passive stake in Cullinan Therapeutics, Inc. (CGEM) via Schedule 13G. The group now beneficially owns 3,009,126 common shares, or 5.1% of CGEM’s 59,014,667 shares outstanding as of 30 July 2025. Citadel Advisors, Citadel Advisors Holdings LP and Citadel GP LLC jointly hold 2,511,191 shares (4.3%), while market-making affiliate Citadel Securities controls 497,935 shares (0.8%). All voting and dispositive power is reported as shared; none of the entities has sole power over the stock. The filing is made under Rule 13d-1(b)/(c), signalling the position is currently passive rather than activist. Kenneth Griffin is deemed a control person through his ownership of the various Citadel general-partner entities. No intent to influence control of the issuer is stated, and the certification confirms the shares were not acquired for activist purposes. The disclosure provides investors with the first confirmation that a high-profile hedge-fund complex has crossed the 5% threshold in CGEM.